ArticleFrontiers in molecular biosciences2025
Investigating the molecular mechanisms of resveratrol in treating diabetic foot ulcers: a comprehensive analysis of network pharmacology and experiment validation.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the Effects and Mechanisms of Neohesperidin Dihydrochalcone on Acute Lung Injury in Mice with Sepsis Using Network Pharmacology and Machine Learning.Current issues in molecular biology · 2026Article
- Revealing key biomarkers and molecular mechanisms associated with di(2-ethylhexyl) phthalate in skin cancer.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers (DFU) are one of the most common and severe complications of diabetes, closely associated with high amputation rates and mortality, and the clinical treatment research is still limited. Previous studies have demonstrated that resveratrol exerts positive effects in wound healing. Therefore, it is necessary to investigate its molecular mechanisms in treating DFU to improve clinical management of this condition. Methods: This study obtained DFU-related omics data from the GEO database and predicted targets for Resveratrol from TCMSP, PharmMapper, and Swiss Target Prediction. Differential analysis, weighted gene co-expression network analysis (WGCNA), and machine learning were used to jointly identify hub Resveratrol/DFU genes (RDGs). SsGSEA analysis was employed to investigate the relationship between RDGs and the DFU immune microenvironment. Single-cell RNA-seq was employed to investigate cellular heterogeneity of RDGs expression. Molecular docking studies examined interactions between RDGs and resveratrol. Finally, immunohistochemistry validated RDGs expression. Results: First, bioinformatics analyses and machine learning algorithms identified Cytidine deaminase (CDA) and Ornithine Decarboxylase 1 (ODC1) as RDGs. Second, ROC curves demonstrated RDGs' strong diagnostic performance for DFU. The ssGSEA algorithm revealed that RDGs partially mediate the immune microenvironment of DFU. Subsequently, scRNA-seq results demonstrated cellular heterogeneity of RDGs expression, which mediates alterations in the pathological microenvironment of DFU and consequently influences its progression. Subsequently, molecular docking revealed strong binding affinity between resveratrol and RDGs, suggesting resveratrol may exert therapeutic effects on DFU by regulating RDG activity through binding. Finally, immunohistochemistry further validated RDG expression, providing strong evidence for RDGs as novel therapeutic targets for DFU. Conclusion: Overall, this study identified RDGs as a key therapeutic target for resveratrol acting on DFU through a series of bioinformatics analyses and machine learning algorithms. Which not only fills the gap in the molecular mechanism of resveratrol treatment for DFU but also provides a novel therapeutic target for DFU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.